Alpha Tau Medical today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the JP Morgan Healthcare week at the Hilton San Francisco Union Square.
Alpha TAU's CEO, Uzi Sofer, will present as follows:
Date: Tuesday, January 8, 2019
Time: 9.15 am (PST)
Room: Franciscan B (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Mr. Sofer will reveal new promising developments of Alpha TAU's breakthrough cancer treatment to be expected in 2019.
"The Showcase is the perfect opportunity to present major steps and exciting news for Alpha TAU in 2019! After a successful year 2018 with $29 Millions in funding and major approvals towards clinical trials in the US, new subsidiaries in the US and Japan and highly promising results achieved in our clinical studies, we are looking forward to another promising year full of new challenges and progress."
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
“We are delighted that Alpha Tau Medical will be presenting at Biotech Showcase this year,” said Sara Demy-Colton, CEO of Demy-Colton. “Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. We are thrilled to, once again, be hosting what we believe will be the great business development opportunity of 2019.”
ABOUT ALPHA TAU MEDICAL
Alpha Tau Medical focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer tumors. Initially developed at Tel Aviv University, Alpha DaRT was shown to be effective and safe for treating different types of cancer in multiple animal studies. The company is running its first clinical trials in several sites in the EU and is currently commencing clinical trials at over 55 leading cancer centers worldwide.
Alpha DaRT enables high-precision alpha radiation for all types of solid tumors. The treatment is delivered by inserting with Radium-224 impregnated seeds into the tumor. When the Radium decays, its short-lived daughters are released from the seed, disperse into the tumor and emit high-energy alpha particles which destroy the tumor. Since the alpha-emitting atoms hardly diffuse in healthy tissue, the Alpha DaRT mainly affects the tumor, sparing the healthy tissue around it.